The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $15.24

Today's change+0.53 +3.60%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $15.24

Today's change+0.53 +3.60%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Infinity Pharmaceuticals Inc Hits New 50-day High

Infinity Pharmaceuticals Inc closed up sharply Wednesday, rallying (U.S.)$0.53 or 3.60% to (U.S.)$15.24 and setting a new 50-day high. Over the last five days, shares have gained 12.14% and 10.35% year to date. Shares have underperformed the S&P 500 by 10.02% during the last year.

Key company metrics

  • Open(U.S.) $14.75
  • Previous close(U.S.) $14.71
  • High(U.S.) $15.35
  • Low(U.S.) $14.73
  • Bid / Ask-- / --
  • YTD % change+10.35%
  • Volume610,599
  • Average volume (10-day)594,080
  • Average volume (1-month)655,513
  • Average volume (3-month)1,007,544
  • 52-week range(U.S.) $8.40 to (U.S.) $18.35
  • Beta1.13
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.27
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue1610--0
Total other revenue--------
Total revenue161000
Gross profit--------
Total cost of revenue--------
Total operating expense53354133
Selling / general / administrative8776
Research & development45283427
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income108-35-41-33
Interest income (expense), net non-operating-5-3-1--
Gain (loss) on sale of assets--------
Other--------
Income before tax103-38-42-33
Income after tax103-38-42-33
Income tax, total--000
Net income103-38-42-33
Total adjustments to net income-2------
Net income before extra. items103-38-42-33
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items101-38-42-33
Inc. avail. to common incl. extra. items101-38-42-33
Diluted net income101-38-42-33
Dilution adjustment--000
Diluted weighted average shares50494848
Diluted EPS excluding extraordinary itemsvalue per share2.03-0.78-0.87-0.68
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share2.03-0.78-0.87-0.68